1.Therapeutic use of diuretics on prevention and treatment of ischemic stroke in elderly patients
Xianglin CHI ; Jianzhong BI ; Shunliang XU ; Yingcui WANG
Chinese Journal of Geriatrics 2016;35(12):1350-1354
Ischemic stroke is mainly seen in the elderly,and more than 90% of the patients have suffered hypertension.Thiazide diuretic is one of the five types of the first-line antihypertensive drugs,its characteristics include relaxation in action,a broad spectrum of anti-hypertension,exact effect,safety,and low price.It has been used for antihypertensive treatment for more than 50 years.As global evidence-based medicine,it is especially suitable for the elderly patients.Thiazide diuretic can effectively reduce the incidence and recurrence of stroke for the elderly hypertensive patients,no matter how it is used alone or in combination with other antihypertensive drugs,the efficiency of thiazide diuretic has withstood the test of time and practice and has been confirmed with clear evidences.Thus,in the elderly patients at high-risk for ischemic stroke,the use of this effective antihypertensive drug should be further emphasized.
2.Thyroid autoimmunity increases the risk of second pregnancy abortion in people with unexplained recurrent abortion
Zhaorui WANG ; Xiaohui JI ; Yihong GUO ; Yingcui LIANG ; Zhuang LI ; Zhuoyao MAI ; Menglan ZHU ; Lujing CHEN ; Hui CHEN
Journal of Chinese Physician 2024;26(11):1607-1612
Objective:To investigate the relationship between thyroid autoimmunity and pregnancy outcome in patients with unexplained recurrent abortion.Methods:A retrospective cohort study of 354 patients with normal thyroid function with recurrent abortion of unknown cause admitted to Sun Yat-sen Memorial Hospital, Sun Yat-sen University from January 2015 to June 2022 was used to detect thyroid antibody and thyroid function levels during pregnancy or early pregnancy. They were divided into TAI group ( n=144) and non-TAI group ( n=210) according to whether thyroid autoimmunity (TAI) was complicated or not. Tracking pregnancy outcomes. Results:Compared with the non-TAI group, the TAI group had a higher proportion of pregnancy outcomes resulting in miscarriage [42.4%(61/144) vs 27.1%(57/210), P=0.004]. In patients with unexplained recurrent abortion, TAI significantly increased the risk of spontaneous abortion [ OR(95% CI): 2.13(1.34, 3.41), P=0.001]. Positive TPOAb or TgAb also increased the risk of spontaneous abortion [ OR(95% CI): 2.18(1.37, 3.50), P=0.001; OR(95% CI): 2.33(1.31, 4.13), P=0.004]. TAI, TPOAb and TgAb had no significant interaction with age ( P=0.482, 0.724, 0.740). Conclusions:TAI is positively associated with the risk of spontaneous abortion in patients with unexplained recurrent abortion. TAI may be a potential risk factor for unexplained recurrent abortion, expanding the diagnosis and treatment of unexplained recurrent abortion.
3.Study on the bioequivalence of Palbociclib capsules in human
Yanchao WANG ; Qian WANG ; Jining DONG ; Yingcui HAO ; Xiujuan LIU ; Chunmei LONG ; Kexin ZHAO
China Pharmacy 2023;34(12):1498-1502
OBJECTIVE To evaluate the bioequivalence of a single oral administration of two palbociclib preparations in healthy subjects under fasting and fed conditions. METHODS Twenty-four healthy subjects (fasting test) and twenty healthy subjects (fed test) were enrolled and divided into two groups. A single-center, open-label, single-dose, two-formulation, two- period, two-sequence and crossover trial was designed. The subjects in the two groups were given the test preparation (domestic Palbociclib capsules) or the reference preparation (original Palbociclib capsules) orally under fasting or fed conditions respectively followed by a 14-day washout period. The blood samples were collected at different time points before and after treatment. After pretreatment, the mass concentration of palbociclib in vivo was determined by high-performance liquid chromatography-tandem mass spectrometry with palbociclib-d8 as the internal standard. SAS V9.4 software was used to calculate the pharmacokinetic parameters and evaluate the bioequivalence. RESULTS Under fasting condition, the cmax of the test preparation and the reference preparation were (71.4±18.1) and (73.8±19.0) ng/mL; AUC0-t were (1 754±412) and (1 793±448) h·ng/mL; AUC0-∞ were (1 851±456) and (1 887±478) h·ng/mL, respectively. Under fed condition, the cmax of the test preparation and the reference preparation were (78.4±18.3) and (81.9±21.7) ng/mL; AUC0-t were (1 905±375) and (1 932±318) h·ng/mL; AUC0-∞ were (2 027±411) and (2 050±342) h·ng/mL, respectively. The 90%CI of the geometric mean ratio of the above parameters was within the acceptable range (80.00%-125.00%). Under fasting and fed conditions, there were 20 and 16 adverse events in 9 and 8 subjects, respectively, but no serious adverse event was observed. CONCLUSIONS Under the fasting and fed conditions, the test preparation and the reference preparation of Pibociclib capsules are bioequivalent and have comparable safety.